David S. Tierney, MD, currently serves as CEO of Icon Bioscience Inc., a privately held ophthalmic drug delivery company. Previously, Dr. Tierney served as President and Chief Operating Officer and Director of Oceana Therapeutics, Inc., which was acquired by Salix Pharmaceuticals, Inc. in December 2011. Previously, Dr. Tierney was the President, Chief Executive Officer and a director of Valera Pharmaceuticals, Inc., until it was acquired by Indevus Pharmaceuticals, Inc., in April 2007. From January 2000 to August 2000, Dr. Tierney served as President of Biovail Technologies, a division of Biovail Corporation, a Canadian drug delivery company, where he had responsibility for all of Biovail's research and development and regulatory and clinical activities. From March 1997 to January 2000, Dr. Tierney was Senior Vice President of Drug Development at Roberts Pharmaceutical Corporation, with responsibility for all research and development activities, and overall responsibility for drug development, medical affairs, worldwide regulatory affairs and chemical process development, as well as being part of the executive management team. From December 1989 to March 1997, Dr. Tierney was at Élan Corporation in a variety of management positions. Dr. Tierney received his medical degree from the Royal College of Surgeons in Dublin, Ireland, and subsequently trained in internal medicine. Dr. Tierney also serves on the board of directors of Bioject Medical Technologies, Inc.